The pretzel-shaped gemcitabine intravesical system (formerly TAR-200) yields a high DFS rate among patients with papillary disease-only NMIBC -- including T1 – that fails to respond to BCG. The ...

Intravenous drip Neoadjuvant dd-MVAC improves overall and disease-specific survival vs gemcitabine-cisplatin in muscle-invasive bladder cancer, a phase 3 trial suggests. Dose-dense methotrexate, ...

Credit: J&J. The New Drug Application is supported by data from cohort 2 of the single-arm, phase 2b SunRISe-1 study. The device remains in the bladder and provides a sustained release of gemcitabine ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Durvalumab plus gemcitabine and cisplatin significantly improved event free survival and overall survival compared with gemcitabine and cisplatin. The Food and Drug Administration (FDA) has approved ...

Punch: Preliminary results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR ...

"The findings are meaningful, as the majority of patients remained free of cancer recurrence at one year despite having papillary tumors that carry a high risk for recurrence and a significant risk of ...

First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for ...

Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients ...